CLC number: R587.2
On-line Access: 2020-03-02
Received: 2019-07-19
Revision Accepted: 2019-11-12
Crosschecked: 2020-02-04
Cited: 0
Clicked: 2724
Cheng-ming Ni, Bing-yu Ling, Xiang Xu, He-ping Sun, Hui Jin, Yu-qiu Zhang, Hong Cao, Lan Xu. CX3CR1 contributes to streptozotocin-induced mechanical allodynia in the mouse spinal cord[J]. Journal of Zhejiang University Science B,in press.Frontiers of Information Technology & Electronic Engineering,in press.https://doi.org/10.1631/jzus.B1900439 @article{title="CX3CR1 contributes to streptozotocin-induced mechanical allodynia in the mouse spinal cord", %0 Journal Article TY - JOUR
CX3CL1受体参与1型糖尿病机械痛的形成创新点:主要探讨CX3CR1在链脲佐菌素(STZ)诱导的1型糖尿病(T1DM)小鼠早期发生的机械痛性神经病变中的作用. 方法:本实验采用健康雄性C57BL/6小鼠与CX3CR1 KO小鼠,体重20~23 g,隔夜禁食12 h(20点至次日8点),并连续三天腹腔注射100 mg/kg的STZ制备T1DM模型.以空腹血糖浓度>11.1 mmol/L且三周后小鼠机械痛阈值明显下降的情况视为T1DM模型制备成功.在小鼠机械痛阈下降的对应时间点,取腰段脊髓背角,采用蛋白质印迹法(western blot)和免疫组化法测定CX3CL1及CX3CR1的表达情况.同时,在发生机械痛阈值下降的第三周时间鞘内给予CX3CR1的中和抗体,进行机械刺激并观察其痛阈值的变化. 结论:STZ诱导的T1DM动物模型在早期表现为显著的机械诱发痛,并伴随脊髓背角CX3CL1/CX3CR1表达上调;在痛阈下降期鞘内给予CX3CR1的中和抗体可抑制糖尿病小鼠的痛行为.与腹腔注射STZ形成T1DM的C57BL/6小鼠相比,CX3CR1 基因敲除的糖尿病小鼠机械痛阈值下降的时间延迟,程度减轻.因此,我们推测CX3CL1/ CX3CR1可能参与T1DM机械痛的形成与发展. 关键词组: Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article
Reference[1]Abbott CA, Malik RA, van Ross ERE, et al., 2011. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care, 34(10):2220-2224. [2]Badr G, Badr BM, Mahmoud MH, et al., 2012. Treatment of diabetic mice with undenatured whey protein accelerates the wound healing process by enhancing the expression of MIP-1α, MIP-2, KC, CX3CL1 and TGF-β in wounded tissue. BMC Immunol, 13:32. [3]Callaghan BC, Cheng HT, Stables CL, et al., 2012. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol, 11(6):521-534. [4]Cameron NE, Eaton SEM, Cotter MA, et al., 2001. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia, 44(11):1973-1988. [5]Cao H, Zhao YQ, 2008. Spinal glial activation contributes to pathological pain states. Neurosci Biobehav Rev, 32(5):972-983. [6]Clark AK, Yip PK, Malcangio M, 2009. The liberation of fractalkine in the dorsal horn requires microglial cathepsin S. J Neurosci, 29(21):6945-6954. [7]Dansereau MA, Gosselin RD, Pohl M, et al., 2008. Spinal CCL2 pronociceptive action is no longer effective in CCR2 receptor antagonist-treated rats. J Neurochem, 106(2):757-769. [8]Dermanovic Dobrota V, Hrabac P, Skegro D, et al., 2014. The impact of neuropathic pain and other comorbidities on the quality of life in patients with diabetes. Health Qual Life Outcomes, 12:171. [9]Guo XX, Wang Y, Wang K, et al., 2018. Stability of a type 2 diabetes rat model induced by high-fat diet feeding with low-dose streptozotocin injection. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 19(7):559-569. [10]Inoguchi T, Li P, Umeda F, et al., 2000. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes, 49(11):1939-1945. [11]Ji RR, Chamessian A, Zhang YQ, 2016. Pain regulation by non-neuronal cells and inflammation. Science, 354(6312):572-577. [12]Kiyomoto M, Shinoda M, Okada-Ogawa A, et al., 2013. Fractalkine signaling in microglia contributes to ectopic orofacial pain following trapezius muscle inflammation. J Neurosci, 33(18):7667-7680. [13]Lee YS, Morinaga H, Kim JJ, et al., 2013. The fractalkine/CX3CR1 system regulates β cell function and insulin secretion. Cell, 153(2):413-425. [14]Lindia JA, McGowan E, Jochnowitz N, et al., 2005. Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain. J Pain, 6(7):434-438. [15]Mika J, Zychowska M, Popiolek-Barczyk K, et al., 2013. Importance of glial activation in neuropathic pain. Eur J Pharmacol, 716(1-3):106-119. [16]Milligan E, Zapata V, Schoeniger D, et al., 2005. An initial investigation of spinal mechanisms underlying pain enhancement induced by fractalkine, a neuronally released chemokine. Eur J Neurosci, 22(11):2775-2782. [17]Moore RA, Wiffen PJ, Derry S, et al., 2014. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev, (4):CD007938. [18]Nishikawa T, Edelstein D, Du XL, et al., 2000. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature, 404(6779):787-790. [19]Oyama T, Miyasita Y, Watanabe H, et al., 2006. The role of polyol pathway in high glucose-induced endothelial cell damages. Diabetes Res Clin Pract, 73(3):227-234. [20]Rajchgot T, Thomas SC, Wang JC, et al., 2019. Neurons and microglia; a sickly-sweet duo in diabetic pain neuropathy. Front Neurosci, 13:25. [21]Souza GR, Talbot J, Lotufo CM, et al., 2013. Fractalkine mediates inflammatory pain through activation of satellite glial cells. Proc Natl Acad Sci USA, 110(27):11193-11198. [22]Sugimoto K, Yasujima M, Yagihashi S, 2008. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des, 14(10):953-961. [23]Svensson CI, Fitzsimmons B, Azizi S, et al., 2005. Spinal p38β isoform mediates tissue injury-induced hyperalgesia and spinal sensitization. J Neurochem, 92(6):1508-1520. [24]Tsuda M, Inoue K, Salter MW, 2005. Neuropathic pain and spinal microglia: a big problem from molecules in ‘small’ glia. Trends Neurosci, 28(2):101-107. [25]Xu AK, Gong Z, He YZ, et al., 2019. Comprehensive therapeutics targeting the corticospinal tract following spinal cord injury. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 20(3):205-218. [26]Yao L, Wu YT, Tian GX, et al., 2017. Acrolein scavenger hydralazine prevents streptozotocin-induced painful diabetic neuropathy and spinal neuroinflammation in rats. Anat Rec (Hoboken), 300(10):1858-1864. [27]Zhang Y, Yan J, Hu R, et al., 2015. Microglia are involved in pruritus induced by DNFB via the CX3CR1/p38 MAPK pathway. Cell Physiol Biochem, 35(3):1023-1033. [28]Zhao H, Alam A, Chen Q, et al., 2017. The role of microglia in the pathobiology of neuropathic pain development: what do we know? Br J Anaesth, 118(4):504-516. [29]Zochodne DW, Verge VMK, Cheng C, et al., 2000. Nitric oxide synthase activity and expression in experimental diabetic neuropathy. J Neuropathol Exp Neurol, 59(9):798-807. Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou
310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn Copyright © 2000 - 2024 Journal of Zhejiang University-SCIENCE |
Open peer comments: Debate/Discuss/Question/Opinion
<1>